

Lochhamer Straße 29, 82152 Martinsried, Germany, Email: info@medicover-genetics.com
Date: 16.03.2023

Report to:

Requesting Physician Name

Address

Contact Information

Order Number	20 2009 1234
Born	DD/MM/YYYY
Sex	
Date test requested:	27.02.2023
Sample collected:	27.02.2023
Sample / Specimen:	DNA from EDTA blood

Order: molecular genetic analysis of Inborn errors of metabolism_2.3

Additional Information /patient phenotype: Inborn errors of metabolism panel

RESULT SUMMARY:

NEGATIVE

No pathogenic/likely pathogenic or variant of uncertain significance (SNV or CNV) was identified.

Conclusion

In the examined genes, no pathogenic variant, likely pathogenic variant or variant of unclear significance could be detected which, according to the current state of knowledge, is or could be causally related to the present clinical symptoms of the patient.

Recommended action

Reanalysis of the data may be performed

- with a focus on other genes in the exome in case of occurrence of new symptoms in the patient.
- after few years based on updated scientific knowledge.

Report released by

John Doe 16.03.2023

johndoe@medicover.com

TEST METHODOLOGY

Sequencing	Enrichment	SNV and CNV Data analysis	data evaluation	Reference genome
Next Generation Sequencing (Illumina)	Twist Human Core Exome plus RefSeq Spikeln	Illumina Dragen Bio-IT Platform VarSeq by GoldenHelix	VarSeq by GoldenHelix	hg38, NCBI GR38
Quality criteria	SNV detection sensitivity	Classification of variants	in silico algorithms	Databases
>30 (precision >99,9%) in min. 75% of bases	99.92 - 99.93 %; confirmation of reported SNV with Sanger sequencing, data analysis with SeqPilot	Richards et al. 2015, Genet Med 17:405; Ellard et al. "ACGS Best Practice Guidelines for Variant Classification 2020"	MaxEntScan, SpliceSiteFinder-like, REVEL	HGMD Professional release, ClinVar, gnomAD

PERCENTAGE OF SEQUENCED BASES WITH COVERAGE >20X

98.35%

ANALYZED GENES

BCS1L(NM_001079866.1), RPIA(NM_144563.2), RPL10(NM_001256577.2), CNNM2(NM_017649.4), MRPL3(NM_007208.3), SACS(NM_014363.5), SAR1B(NM_016103.3), MSMO1(NM_006745.4), SC5D(NM_006918.4), SCO1(NM_004589.3), SCO2(NM_005138.2), SCP2(NM_002979.4), SDHA(NM_004168.3), SDHB(NM_003000.2), SDHD(NM_003002.3), SEC23B(NM_006363.4), SGSH(NM_000199.3), SI(NM_001041.3), ST3GAL3(NM_006279.3), ST3GAL5(NM_003896.3), SKIV2L(NM_006929.4), SLC40A1(NM_014585.5), SLC12A3(NM_000339.2), SLC16A1(NM_003051.3), SLC17A5(NM_012434.4), SLC18A2(NM_003054.4), SLC19A2(NM_006996.2), SLC22A5(NM_003060.3), SLC25A1(NM_005984.4), SLC25A12(NM_003705.4), SLC25A13(NM_014251.2), SLC25A15(NM_014252.3), SLC25A3(NM_005888.3), SLC25A4(NM_001151.3), SLC2A1(NM_006516.2), SLC2A2(NM_000340.1), SLC35A1(NM_006416.4), SLC35A2(NM_001042498.2), SLC3A1(NM_000341.3), SLC5A1(NM_000343.3), SLC6A3(NM_001044.4), SLC6A8(NM_005629.3), SLC7A7(NM_001126106.2), SLC7A9(NM_014270.4), SMPD1(NM_000543.4), BTD(NM_000060.4), SPG7(NM_003119.3), SPR(NM_003124.4), SPTLC1(NM_006415.3), SPTLC2(NM_004863.3), SSBP1(NM_003143.2), SSR4(NM_001204526.1), STS(NM_000351.5), SUCLA2(NM_003850.2), SUCLG1(NM_003849.3), SUOX(NM_001032386.1), SURF1(NM_003172.3), TALDO1(NM_006755.1), TAT(NM_000353.2), TAZ(NM_000116.4), TWNK(NM_021830.4), TCN2(NM_000355.3), TFR2(NM_003227.3), TH(NM_199292.2), ACO2(NM_001098.2), TIMM8A(NM_004085.3), TK2(NM_004614.4), ACOX1(NM_004035.6), TOP3A(NM_004618.4), TREX1(NM_033629.4), TSFM(NM_005726.5), TPPA(NM_000370.3), TUFM(NM_003321.4), C1QBP(NM_001212.3), UGT1A1(NM_000463.2), UMOD(NM_003361.3), UMPS(NM_000373.3), UQCRCB(NM_006294.4), UROD(NM_000374.4), UROS(NM_000375.2), VPS33B(NM_018668.4), WARS2(NM_015836.3), WFS1(NM_006005.3), XDH(NM_000379.3), LPIN1(NM_145693.2), MCOLN1(NM_020533.2), NSDHL(NM_015922.2), RXYLT1(NM_014254.2), FBXL4(NM_001278716.1), CA5A(NM_001739.1), GFM1(NM_024996.5), ABCG5(NM_022436.2), ABCG8(NM_022437.2), ELAC2(NM_018127.6), SLC25A20(NM_000387.5), HTRA2(NM_013247.4), SLC25A19(NM_021734.4), MRPS2(NM_016034.4), MRPS22(NM_020191.2), NPC2(NM_006432.3), PINK1(NM_032409.2), AMN(NM_030943.3), COG5(NM_006348.3), GTPBP3(NM_032620.3), PIGT(NM_015937.5), CAT(NM_001752.3), MICU1(NM_001195518.1), GPHN(NM_020806.4), CBS(NM_000071.2), PUS1(NM_025215.5), XYLT1(NM_022166.3), XYLT2(NM_022167.3), CHCHD10(NM_213720.2), HAMP(NM_021175.3), ALG9(NM_024740.2), LRPPRC(NM_133259.3), RBCK1(NM_031229.3), ABHD12(NM_001042472.2), PANK2(NM_153638.3), NDUFAF5(NM_024120.4), SAMHD1(NM_015474.3), GDAP1(NM_018972.2), APTX(NM_175073.2), SFXN4(NM_213649.1), SLC52A3(NM_033409.3), MGME1(NM_052865.3), DNAJC5(NM_025219.2), TRAP1(NM_016292.2), SLC19A3(NM_025243.3), NFU1(NM_001002755.2), UPB1(NM_016327.2), LIAS(NM_006859.3), MRPS34(NM_023936.1), MRPL44(NM_022915.3), MCEE(NM_032601.3), COQ8A(NM_020247.4), MFN2(NM_014874.3), BCKDK(NM_005881.3), LARS2(NM_015340.3), SLC39A4(NM_130849.3), CHSY1(NM_014918.4), APOA5(NM_052968.4), RRM2B(NM_015713.4), TRNT1(NM_182916.2), TPK1(NM_022445.3), AASS(NM_005763.3), NGLY1(NM_018297.3), SARS2(NM_017827.3), ACY1(NM_000666.2), PDSS1(NM_014317.4), NT5C3A(NM_001002010.2), PGAP2(NM_014489.3), B3GALT6(NM_080605.3), TRPM6(NM_017662.4), NAGS(NM_153006.2), FKRP(NM_024301.4), COA6(NM_001012985.2), TMEM199(NM_152464.2), ALG1(NM_019109.4), HSD3B7(NM_025193.3), NAXE(NM_144772.2), RNASEH1(NM_002936.4), ATP6V0A2(NM_012463.3), IER3IP1(NM_016097.4), ADA(NM_000022.3), COG4(NM_015386.2), COG6(NM_020751.2), COG7(NM_153603.3), COG8(NM_032382.4), LDLRAP1(NM_015627.2), RTN4IP1(NM_032730.5), PMPCA(NM_015160.2), ATPAF2(NM_145691.3), NDUFAF1(NM_016013.3), MMAA(NM_172250.2), DCXR(NM_016286.3), COQ8B(NM_024876.3),

PSAT1(NM_058179.3), POMGNT1(NM_001243766.1), MTO1(NM_012123.3), MMAB(NM_052845.3), ALG12(NM_024105.3), CHKB(NM_005198.4), MECR(NM_016011.3), COQ4(NM_016035.4), CHST3(NM_004273.4), POMT2(NM_013382.5), ISCA2(NM_194279.3), SLC25A22(NM_001191061.1), PCSK9(NM_174936.3), GLRX5(NM_016417.2), SLC35C1(NM_018389.4), B3GLCT(NM_194318.3), COQ6(NM_182476.2), NUBPL(NM_025152.2), TRIT1(NM_017646.5), VIPAS39(NM_022067.3), CLDN16(NM_006580.3), NDUFA11(NM_175614.4), NDUFB11(NM_019056.6), SUMF1(NM_182760.3), CLDN19(NM_148960.2), COA8(NM_032374.4), L2HGDH(NM_024884.2), SLC25A26(NM_173471.3), TPP1(NM_000391.3), CLN3(NM_000086.2), CLN5(NM_006493.2), CLN6(NM_017882.2), CLN8(NM_018941.3), SLC35D1(NM_015139.2), CLPP(NM_006012.2), SLC39A14(NM_001128431.2), SLC39A8(NM_001135146.1), QRSL1(NM_018292.4), AARS2(NM_020745.3), NDUFAF4(NM_014165.3), SERAC1(NM_032861.3), FARS2(NM_006567.4), RMND1(NM_017909.3), FA2H(NM_024306.4), UQCC2(NM_032340.3), DYM(NM_017653.3), PDHX(NM_003477.2), ABHD5(NM_016006.4), RARS2(NM_020320.4), ACAD9(NM_014049.4), NHLRC1(NM_198586.2), MPC1(NM_016098.3), VARS2(NM_001167734.1), AGK(NM_018238.3), COQ7(NM_016138.4), ADAR(NM_001111.4), COX10(NM_001303.3), COX15(NM_004376.6), COX6A1(NM_004373.3), COX6B1(NM_001863.4), COX7B(NM_001866.2), GMPPB(NM_021971.2), CP(NM_000096.3), PEX26(NM_017929.5), ABAT(NM_020686.5), GNPTG(NM_032520.4), LMBRD1(NM_018368.3), PDSS2(NM_020381.3), ALG3(NM_005787.5), TRMT5(NM_020810.3), ALG6(NM_013339.3), ALG8(NM_024079.4), PNPT1(NM_033109.4), CPOX(NM_000097.5), PIGO(NM_032634.3), CPS1(NM_001875.4), CPT1A(NM_001876.3), ETHE1(NM_014297.4), CPT2(NM_000098.2), DOLK(NM_014908.3), DHTKD1(NM_018706.6), TTC37(NM_014639.3), TIMM50(NM_001001563.3), GNE(NM_001128227.2), VKORC1(NM_024006.5), PGAP3(NM_033419.4), CISD2(NM_001008388.4), GLYCTK(NM_145262.3), YARS2(NM_001040436.2), TACO1(NM_016360.3), BOLA3(NM_212552.2), CHST14(NM_130468.3), MMACHC(NM_015506.2), FLAD1(NM_025207.4), MFF(NM_001277062.1), G6PC3(NM_138387.3), MOGS(NM_006302.2), CTH(NM_001902.5), MARS2(NM_138395.3), HOGA1(NM_138413.3), CTNS(NM_004937.2), SLC25A46(NM_138773.3), MMADHC(NM_015702.2), COQ2(NM_015697.7), CTSC(NM_001814.5), CTSD(NM_001909.4), COQ9(NM_020312.3), SLC30A10(NM_018713.2), CTSK(NM_000396.3), TANGO2(NM_152906.6), C19orf12(NM_031448.4), CUBN(NM_001081.3), TRMU(NM_018006.4), ANO10(NM_018075.4), MTPAP(NM_018109.3), DARS2(NM_018122.4), ATAD3A(NM_001170535.1), CARS2(NM_024537.3), COAT(NM_023077.2), CYC1(NM_001916.4), SRD5A3(NM_024592.4), POMGNT2(NM_032806.5), TTC19(NM_017775.3), TRMT10C(NM_017819.3), PIGV(NM_017837.3), CYP27A1(NM_000784.3), TMEM70(NM_017866.5), SLC25A38(NM_017875.2), FAR1(NM_032228.5), NARS2(NM_024678.5), NADK2(NM_001085411.2), CYP7B1(NM_004820.4), HGSNAT(NM_152419.2), DARS1(NM_001349.3), C12orf65(NM_152269.4), DBH(NM_000787.3), FOXRED1(NM_017547.3), COX20(NM_198076.5), DBT(NM_001918.3), DDC(NM_000790.3), ACSF3(NM_174917.4), IBA57(NM_001010867.3), SLC6A19(NM_001003841.2), LYRM7(NM_181705.3), NDUFAF2(NM_174889.4), CCDC115(NM_032357.3), COX14(NM_032901.3), D2HGDH(NM_152783.4), SLC25A42(NM_178526.4), MFSD8(NM_152778.2), DGUOK(NM_080916.2), DHCR24(NM_014762.3), B3GALNT2(NM_152490.4), DHCR7(NM_001360.2), DHFR(NM_000791.3), NDUFAF6(NM_152416.3), ISCA1(NM_030940.3), DHODH(NM_001361.4), MAGT1(NM_032121.5), PPA2(NM_176869.2), PNPLA8(NM_015723.4), DNAJC12(NM_021800.2), WDR45(NM_007075.3), DLAT(NM_001931.4), DLD(NM_000108.4), ABCA1(NM_005502.3), ADSL(NM_000026.3), FASTKD2(NM_014929.3), EPG5(NM_020964.2), DNA2(NM_001080449.2), EARS2(NM_001083614.1), LIPT1(NM_015929.3), MTFMT(NM_139242.3), GNPTAB(NM_024312.4), MSTO1(NM_018116.3), GFM2(NM_032380.4), SLC25A32(NM_030780.4), IARS2(NM_018060.3), DNM1L(NM_012062.4), DNM2(NM_001005360.2), ISCU(NM_213595.3), NDUFAF3(NM_199069.1), DPAGT1(NM_001382.3), DPM1(NM_001317034.1), DPM2(NM_003863.3), DPM3(NM_153741.1), DPYD(NM_000110.3), DPYS(NM_001385.2), ATP13A2(NM_022089.3), RFT1(NM_052859.3), SLC52A2(NM_024531.4), TUSC3(NM_006765.3), PNPO(NM_018129.3), SLC46A1(NM_080669.5), DNAJC19(NM_145261.3), FDX2(NM_001031734.3), PARS2(NM_152268.3), CLPB(NM_001258392.2), TMEM165(NM_018475.4), TMEM126B(NM_018480.4), SLC6A20(NM_020208.3), EBP(NM_006579.2), TYMP(NM_001257989.1), AFG3L2(NM_006796.2), ECHS1(NM_004092.3), AGA(NM_000027.3), AGL(NM_000642.2), ALG11(NM_001004127.2), AGPS(NM_003659.3), ENO3(NM_053013.3), NDUFAF8(NM_001086521.1), MICOS13(NM_001308240.1), SDHAF1(NM_001042631.2), AGXT(NM_000030.2), EPM2A(NM_005670.3), ETFA(NM_000126.3), ETFB(NM_001985.2), ETFDH(NM_004453.3), EXT1(NM_000127.2), EXT2(NM_207122.1), FAH(NM_000137.2), FBP1(NM_000507.3), FKTN(NM_006731.2), FDXR(NM_024417.4), FECH(NM_000140.3), FGFR2(NM_000141.4), FH(NM_000143.3), ATP8B1(NM_005603.4), LIPT2(NM_001144869.2), CRPPA(NM_001101426.3), FMO3(NM_006894.5), FOLR1(NM_016725.2), AKR1D1(NM_005989.3), ALAD(NM_000031.5), FXN(NM_000144.4), ALAS2(NM_000032.4), FTCD(NM_006657.2), PET100(NM_001171155.1), FUCA1(NM_000147.4), FUT8(NM_178155.2), ALDH3A2(NM_000382.2), G6PC(NM_000151.3), ALDH4A1(NM_003748.3), SLC37A4(NM_001164277.1), GAA(NM_000152.4), ALDH5A1(NM_001080.3), GABRG2(NM_000816.3), GALC(NM_000153.3), GALE(NM_000403.3), GALK1(NM_000154.1), GALNS(NM_000512.4), GALNT3(NM_004482.3), GALT(NM_000155.3), GAMT(NM_000156.5), ALDOA(NM_184041.2), GARS1(NM_002047.3), ALDOB(NM_000035.3), GATM(NM_001482.2), GBA(NM_000157.3), GBE1(NM_000158.3), GCDH(NM_000159.3), GCH1(NM_000161.2), ABCB11(NM_003742.2), GFER(NM_005262.2), GFPT1(NM_002056.3), CBLIF(NM_005142.2), GK(NM_000167.5), GLA(NM_000169.2), GLB1(NM_000404.3), GCLC(NM_001498.3), GLDC(NM_000170.2), GLRA1(NM_000171.3), GLS(NM_014905.4), GLUD1(NM_005271.4), GLUL(NM_002065.6), GM2A(NM_000405.4), ALPL(NM_000478.5), GNMT(NM_018960.5), GNPAT(NM_014236.3), GNS(NM_002076.3), SETX(NM_015046.5), GPD1(NM_005276.3), ABCB4(NM_000443.3), AMACR(NM_014324.5), GRHPR(NM_012203.1), GSS(NM_000178.3), GUSB(NM_000181.3), GYG1(NM_004130.3), GYS1(NM_002103.4), GYS2(NM_021957.3), AMT(NM_000481.3), HAAO(NM_012205.2), HADH(NM_005327.4), ABCB7(NM_001271696.1), HSD17B10(NM_004493.2), HADHA(NM_000182.4), HADHB(NM_000183.2), HARS2(NM_012208.3), HCCS(NM_005333.4),

HCFC1(NM_005334.2), HEXA(NM_000520.5), HEXB(NM_000521.3), HFE(NM_000410.3), HJV(NM_213653.3),
 HGD(NM_000187.3), HIBCH(NM_014362.3), HLCS(NM_000411.6), HMBS(NM_000190.3), HMGCL(NM_000191.2),
 HMGCS2(NM_005518.3), HPD(NM_002150.2), HPRT1(NM_000194.2), HPS1(NM_000195.4), HSD17B4(NM_000414.3),
 HSPD1(NM_002156.4), HYAL1(NM_153281.1), IDH2(NM_002168.3), IDS(NM_000202.7), IDUA(NM_000203.4),
 APOA1(NM_000039.2), APOB(NM_000384.2), APOC2(NM_000483.4), ABCD1(NM_000033.3), APOE(NM_000041.3),
 ITPA(NM_033453.3), IVD(NM_002225.3), KARS1(NM_001130089.1), APRT(NM_000485.2), KYNU(NM_003937.2),
 LAMP2(NM_002294.2), LARGE1(NM_004737.5), LARS1(NM_020117.10), LBR(NM_002296.3), LCAT(NM_000229.1),
 LCT(NM_002299.3), LDHA(NM_005566.3), COG1(NM_018714.2), LDLR(NM_000527.4), LIPA(NM_000235.3),
 ARG1(NM_000045.3), LPL(NM_000237.2), ABCD4(NM_005050.3), MAN1B1(NM_016219.4), MAN2B1(NM_000528.3),
 MANBA(NM_005908.3), MAOA(NM_000240.3), MAT1A(NM_000429.2), MCCC1(NM_020166.4), MCCC2(NM_022132.4),
 CHST6(NM_021615.4), MDH2(NM_005918.3), MGAT2(NM_002408.3), MIPEP(NM_005932.3), ARSA(NM_000487.5),
 ARSB(NM_000046.3), MLYCD(NM_012213.2), ALDH6A1(NM_005589.3), ARSL(NM_000047.2), MOCS1(NM_005943.5),
 MOCS2(NM_176806.3), MPDU1(NM_004870.3), MPI(NM_002435.2), MPV17(NM_002437.4), ASA1(NM_177924.4), MT-
 ATP6(MT-ATP6), MT-ATP8(MT-ATP8), MT-CO1(MT-CO1), MT-CO2(MT-CO2), MT-CO3(MT-CO3), MT-CYB(MT-CYB),
 MTHFR(NM_005957.4), MT-ND1(MT-ND1), MT-ND2(MT-ND2), MT-ND3(MT-ND3), MT-ND4(MT-ND4), ASL(NM_000048.3),
 MT-ND4L(MT-ND4L), MT-ND5(MT-ND5), MT-ND6(MT-ND6), MTTP(NM_000253.3), MTR(NM_000254.2), MT-RNR1(MT-
 RNR1), MTRR(NM_002454.2), MT-TA(MT-TA), MT-TC(MT-TC), MT-TD(MT-TD), MT-TE(MT-TE), MT-TF(MT-TF), MT-TG(MT-
 TG), MT-TH(MT-TH), MT-TI(MT-TI), MT-TK(MT-TK), MT-TL1(MT-TL1), MT-TL2(MT-TL2), MT-TM(MT-TM), MT-TN(MT-TN),
 MT-TP(MT-TP), MT-TQ(MT-TQ), MT-TR(MT-TR), MT-TS1(MT-TS1), MT-TS2(MT-TS2), MT-TV(MT-TV), MT-TW(MT-TW), MT-
 TY(MT-TY), TRIM37(NM_015294.4), MMUT(NM_000255.3), MVK(NM_000431.3), ASPA(NM_000049.2),
 ASS1(NM_000050.4), NAGA(NM_000262.2), NAGLU(NM_000263.3), NDUFA1(NM_004541.3), NDUFA10(NM_004544.3),
 NDUFA2(NM_002488.4), NDUFA4(NM_002489.3), NDUFA6(NM_002490.4), NDUFA9(NM_005002.4),
 NDUFB3(NM_002491.2), NDUFB8(NM_005004.3), NDUFS1(NM_005006.6), NDUFS2(NM_004550.4),
 NDUFS3(NM_004551.2), NDUFS4(NM_002495.3), NDUFS6(NM_004553.4), NDUFS7(NM_024407.4),
 NDUFS8(NM_002496.3), NDUFV1(NM_007103.3), NDUFV2(NM_021074.4), NEU1(NM_000434.3), NNT(NM_012343.3),
 PNP(NM_000270.3), NPC1(NM_000271.4), ATIC(NM_004044.6), OAT(NM_000274.3), OCRL(NM_000276.3),
 OPA1(NM_015560.2), OPA3(NM_025136.3), ATP5F1D(NM_001687.4), OTC(NM_000531.5), OXCT1(NM_000436.3),
 PAH(NM_000277.1), PC(NM_001040716.1), PCBD1(NM_000281.3), PCCA(NM_000282.3), PCCB(NM_000532.4),
 ATP6AP1(NM_001183.5), ATP7A(NM_000052.6), ACAD8(NM_014384.2), ATP7B(NM_000053.3), PCK1(NM_002591.3),
 AIFM1(NM_004208.3), ALDH7A1(NM_001182.4), PDHA1(NM_000284.3), PDHB(NM_000925.3), PEPD(NM_000285.3),
 PEX1(NM_000466.2), PEX10(NM_153818.1), PEX11B(NM_003846.2), PEX12(NM_000286.2), PEX13(NM_002618.3),
 PEX14(NM_004565.2), PEX16(NM_057174.2), PEX3(NM_003630.2), PEX6(NM_000287.3), PEX7(NM_000288.3),
 PFKM(NM_000289.5), PGAM2(NM_000290.3), PGK1(NM_000291.3), ACADM(NM_000016.5), AUH(NM_001698.2),
 PGM1(NM_002633.2), PGM3(NM_001199917.1), PHGDH(NM_006623.3), PHKA1(NM_002637.3), PHKA2(NM_000292.2),
 PHKB(NM_000293.2), PHKG2(NM_000294.2), PHYH(NM_006214.3), PIGA(NM_002641.3), PIGL(NM_004278.3),
 PIGN(NM_176787.4), ACADS(NM_000017.3), PLA2G6(NM_003560.2), ACADSB(NM_001609.3), PMM2(NM_000303.2),
 PMPCB(NM_004279.2), POLG(NM_002693.2), POLG2(NM_007215.3), ACADVL(NM_000018.3), POMT1(NM_007171.3),
 POR(NM_000941.2), B3GAT3(NM_012200.3), B4GALT1(NM_001497.3), CTSA(NM_000308.3), PDP1(NM_018444.3),
 PPOX(NM_000309.3), ACAT1(NM_000019.3), B4GALT7(NM_007255.2), BAAT(NM_001701.3), PPT1(NM_000310.3),
 PRKAG2(NM_016203.3), PRODH(NM_016335.4), PRPS1(NM_002764.3), LONP1(NM_004793.3), PSAP(NM_002778.3),
 PTS(NM_000317.2), PEX19(NM_002857.3), PEX2(NM_000318.2), PEX5(NM_001131025.1), PYCR1(NM_006907.3),
 ALDH18A1(NM_002860.3), PYGL(NM_002863.4), PYGM(NM_005609.3), QDPR(NM_000320.2), BCAT2(NM_001190.3),
 BCKDHA(NM_000709.3), BCKDHB(NM_183050.3), RBP4(NM_006744.3)

LIST OF EXONS WITH COVERAGE <20X

Chr.	Pos.	Gene	Exon	Transcript	Mean Coverage (Min/Max)
Chr1	1167654..1168653	B3GALT6	Exon 01	NM_080605.3	126.19 (0/284)
Chr1	1447644..1447858	ATAD3A	Exon 01	NM_001170535.1	65.90 (15/99)
Chr1	20960037..20960433	PINK1	Exon 01	NM_032409.2	124.28 (14/206)
Chr1	155580825..155580904	MSTO1	Exon 03	NM_018116.3	19.56 (14/26)
Chr1	155581475..155581623	MSTO1	Exon 06	NM_018116.3	17.73 (9/36)
Chr5	36241596..36241905	NADK2	Exon 01	NM_001085411.2	56.77 (11/117)
Chr5	161529555..161529684	GABRG2	Exon 06	NM_198903.2	2.26 (0/3)
Chr8	42995635..42995762	HGSNAT	Exon 01	NM_152419.2	21.00 (6/30)
Chr10	26991086..26991128	PDSS1	Exon 02	NM_001321978.1	0.30 (0/1)
Chr10	26991086..26991128	PDSS1	Exon 02	NM_014317.4	0.30 (0/1)
Chr11	77813935..77813999	ALG8	Exon 13	NM_001007027.2	2.00 (2/2)
Chr12	58185743..58185815	TSFM	Exon 05	NM_001172696.1	0.00 (0/0)
Chr14	96001422..96001726	GLRX5	Exon 01	NM_016417.2	73.83 (14/124)
Chr15	101791337..101791666	CHSY1	Exon 01	NM_014918.4	49.13 (7/107)
Chr16	17564286..17564658	XYLT1	Exon 01	NM_022166.3	30.42 (3/70)
Chr16	66581869..66581887	TK2	Exon 03	NM_001271934.1	11.89 (11/12)

Chr19	47249401..47249692	STRN4	Exon 01	NM_013403.2	60.62 (4/117)
Chr22	19166088..19166191	SLC25A1	Exon 01	NM_005984.4	40.98 (6/67)

TECHNICAL LIMITATIONS

mosaics (<20%); indels >21bp; repeat expansions; repetitive regions; variants in: homopolymeric regions or regions of high sequence homology, unenriched regions (untranslated regions, introns, promoter and enhancer regions) or enriched but insufficiently covered regions; variants in mt-DNA (VAF<20%); determination of the phase of multiple variants in one gene; balanced genomic rearrangements

CLASSES OF VARIANTS

Class 5: pathogenic variant – are reported, posterior probability >99 %

Class 4: likely pathogenic variant – are reported, posterior probability >90 %

Class 3: uncertain significance – only be listed in the report if posterior probability is >67.5 %

Class 2: likely benign – not reported, posterior probability <10 %

Class 1: benign – not reported, posterior probability <0,1 %

ACMG CRITERIA

1. Criteria for pathogenic evidence

PVS1: Null variant in a gene where loss of function (LOF) is a known mechanism of disease; PS1: same amino acid change as a previously established pathogenic variant regardless of nucleotide change; PS2/PM6: de novo in a patient with the disease and no family history; PS3: well-established functional studies supportive of a damaging effect on the gene or gene product; PS4: the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls/was identified in unrelated affected individuals; PM1: missense variant located in a mutational hot spot and/or critical and well-established functional domain; PM2: absent from controls (or at extremely low frequency) in Genome Aggregation Database (gnomAD); PM3: for recessive disorders, detected in homozygous state or together with another (not benign or likely benign) variant; PM4: protein length changes as a result of in-frame deletions/insertions in a non-repeating region or stop-loss variants; PM5: missense change at an amino acid residue where a different missense change determined to be (likely) pathogenic has been seen before; PP1: co-segregation with disease in multiple affected family members; PP2: missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease; PP3: multiple lines of computational evidence support a deleterious effect on the gene or gene product; PP4: patient's phenotype or family history is (highly) specific for variations in the affected gene; PP5: reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.

2. Criteria for benign evidence

BA1: allele frequency is >5% if recessive and 0.5% if dominant in gnomAD; BS1: allele frequency is greater than expected for disorder; BS2: observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age; BS3: well-established functional studies show no damaging effect on protein function or splicing; BS4: lack of segregation with disease; BP1: missense variant in a gene for which primarily truncating variants are known to cause disease OR for loss-of-function variants in a gene where the disease is caused by gain-of-function variants; BP2: observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern; BP3: in-frame deletions/insertions in a repetitive region without a known function; BP4: multiple lines of computational evidence suggest no impact on gene or gene product; BP5: variant found in a case with an alternate molecular basis for disease; BP6: reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation; BP7: a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence nor the creation of a new splice site AND the nucleotide is not highly conserved.

According to Ellard et al. 2020, the strength level of criteria PVS1, PS1, PS2, PS3, PS4, PM1, PM3, PM4, PM5, PP1, PP4, BP2, and BP4 can be modified depending on the cogency of the evidence.

Report released by

John Doe 16.3.2020

johndoe@medicover.com